- Min.Order :1 Kilogram
- Purity: 99%
- Payment Terms : D/A,D/P,T/T
Keywords
Biapenem 120410-24-4 C15H18N4O4S
Quick Details
- Appearance:detailed in specifcations
- Application:Aripiprazole Intermediate
- PackAge:as needed
- ProductionCapacity:500|Metric Ton|Month
- Storage:Keep in dry and cool condition
- Transportation:by air or sea
Superiority:
Our Services
1.Certificate Of Analysis (COA)
2.Material Safety Data Sheet (MSDS)
3.Route of synthesis (ROS)
4.Method of Aanlysis (MOA)
5.Nuclear Magnetic Resonance (NMR)
6.Packing pictures and loading video before loading
7.Free Sample
9.Factory audit
10.Strong after-sale service
Company information
Henan Sunlake Enterprise Corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East , Africa , South America and some other countries and areas.We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team.We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate.
Details:
| Biapenem Basic information |
| New carbapenem antibiotic (carbapenem family members) Antibacterial activity Indications Intellectual property status Application |
| Product Name: | Biapenem |
| Synonyms: | 6-[[(4r,5s,6s)-2-carboxy-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5h-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt;BIAPENEM;6-[[(4R,5S,6S)-2-Carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt;(4R,5S,6S)-3-(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate;6-[[(4R,5S,6S)-2-Carboxylato-6β-[(1R)-1-hydroxyethyl]-4α-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5H-pyrazolo[1,2-a]-s-triazol-4-ium;6-[[(4R,5S,6S)-2-Carboxylato-6β-[(R)-1-hydroxyethyl]-4α-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium;6-[[(4R,5β)-2-Carboxylato-4α-methyl-6β-[(R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium;L-627 |
| CAS: | 120410-24-4 |
| MF: | C15H18N4O4S |
| MW: | 350.39 |
| EINECS: | 204-352-8 |
| Product Categories: | API;chiral;Antibacterial;pharmaceutical intermediates;Chiral Compounds;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Pharmaceutical intermediate;Pharmaceutical raw material;L-627, LJC 10627;Inhibitors |
| Mol File: | 120410-24-4.mol |
|
|
|
| Biapenem Chemical Properties |
| mp | 265-271°C (dec.) |
| storage temp. | -20 C Freezer |
| CAS DataBase Reference | 120410-24-4(CAS DataBase Reference) |
| Safety Information |
| Biapenem Usage And Synthesis |
| New carbapenem antibiotic (carbapenem family members) |
Biapenem, together with several drugs developed in different companies in the United State, Japan, and China, all belong to the rapid-developing carbapenem family members. It is white to yellowish white crystalline powder, and is a kind of carbapenem-class antibiotics for injection developed by both the Lederle Company in Japan and the Cyanamid Company in the united state in 1989. It has a broad antibacterial spectrum and has an excellent bactericidal effect on Gram-negative, Gram-positive, aerobic and anaerobic bacteria. The C1 position of its structure contains a 1β-methyl group which can enable drugs to be stable to the effects of the dehydropeptidase I (DHP-I) in the human kidney without the necessity to be combined with DHP-I inhibitor for therapy, and thus reducing its renal toxicity, and is also stable to β- lactamase stability; it also has excellent pharmacokinetic properties and low toxicity; It has excellent therapeutic effect on treating various diseases such as concurrent intra-abdominal infections, plastic surgery infections, gynecological infections, ENT infections, lower respiratory tract infections (including bacterial pneumonia), and also concurrent urinary tract infections with a good tolerance and a lower incidence of adverse reactions. A notable feature of this product is the existence of the 1β-methyl carbapenem (containing bicyclic triazole) located at the S at 2-position. Structure-function relationship studies have showed that the presence of quaternary ammonium cation located in the side chain is the key that affects the outer membrane permeability, making the inhibitory effect of the product on Pseudomonas aeruginosa and anaerobic bacteria be 2 to 4 times as potent as that of imipenem, and the inhibitory effect on the drug-resistant Pseudomonas aeruginosa be 4 to 8 times as potent as that of meropenem, and moreover, making it more effective in treating Acinetobacter spp, anaerobic bacteria than ceftazidime. Thus, it is promising that it is expected to become a novel first-line drug for treating severe infection. The general dose for intravenously infusion of Biapenem is about 300mg with time being 30 ~ 60min at 2 times per day. |
| Antibacterial activity |
Studies have shown that biapenem has broad-spectrum and potent antibacterial activity against G+ bacteria, G- as well as anaerobic bacteria, etc. MIC90 range of this product against 456 clinical isolates of G + bacteria was 0.006 ~ 3.13μg / ml; for 1145 G- bacteria, the MIC90 range is 0.1 ~ 3.13μg/ml with its antibacterial activity being 2 times as strong as imipenem; for most anaerobes, the MIC90 range is 0.05 ~ 1.56μg/ml. Biapenem has broad-spectrum antimicrobial activity. The antimicrobial activity of it is similar as that of imipenem and meropenem, and stronger than that latamoxef and ceftazidime. The MIC value and MBC values are ??similar with each other for this drug. Upon MIC concentration, it can cause morphological changes of Pseudomonas aeruginosa and Escherichia coli; upon a concentration higher than MIC, the bacteria exhibits lytic phenomenon. Staphylococcus aureus, GPB, Streptococcus pyogenes and Streptococcus pneumoniae are highly sensitive to the drug; but methicillin-resistant Staphylococcus aureus and GPB are also resistant to this drug. In addition, this product also has excellent antibacterial activity against Bacteriodes fragilis also with MIC90 being 1.56μg /ml. The research of Ichiro Murakami has shown that this antibacterial activity against clinical isolates of G + bacteria and Enterobacteriaceae of this drug is similar as or slightly weaker than that of imipenem, but with a stronger anti-bacterial activity against Enterobacteriaceae family than imipenem; for non G- fermentation bacteria, especially Pseudomonas aeruginosa and GM-resistant Pseudomonas aeruginosa, this antibacterial activity of this drug is two times as strong as imipenem. Biapenem has a high affinity to the protein PBP2 and PBP4 of Pseudomonas aeruginosa, exhibiting its excellent antibacterial activity and low endotoxin release property during the bactericidal process. In 2001, the study of Japanese Scholars (Hiraishi.T) had shown that the transient bactericidal action of biapenem against Pseudomonas aeruginosa PAO1 is superior to that of meropenem. In 2005, during the comparison of transient bactericidal effects against Pseudomonas aeruginosa for biapenem, imipenem, and meropenem, Japanese scholars (Shimauchi.C) found that biapenem has a best bactericidal activity within the same treatment time. The above information |
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View